Despite substantial progress in cancer treatment, durable benefit is still frequently limited by the ability of tumors to adapt under therapeutic pressure.

The study of experimental evolution in Escherichia coli has provided unprecedented insights into the mechanisms of adaptive mutations, elucidating how populations diverge and optimise their fitness ...